Plus   Neg

Cellectar Biosciences Inc. (CLB) Is Climbing On Study Results

Cellectar Biosciences Inc. (CLRB) announced Tuesday morning that its Phase 1b clinical trial of CLR 131, for the treatment of relapsed/refractory multiple myeloma, demonstrated overall survival of 19.4 months.

Cellectar Biosciences has gapped open higher this morning and is now up 0.57 at $3.86 on above average volume. The stock has jumped to a 2-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT